Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder

Advances in Experimental Medicine and Biology

Volumn 462, Issue , 1999, Pages 425-435

  Grossfeld, G D ^a   Muscheck, M ^a   Stein, J P ^a   Chew, K ^a   Cote, R J ^a   Ginsberg, D A ^a   Waldman, F M ^a   Carroll, P R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

BLADDER CARCINOMA; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME REPLICATION; CONFERENCE PAPER; DNA SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0033281544     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4737-2_33     Document Type: Conference Paper

References (41)

1. Ordering S phase and M phase in the cell cycle
2. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age
3. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia
4. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer
5. Structural evidence for the authenticity of the human retinoblastoma gene
6. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma
7. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer
8. Molecular genetic alterations in superficial and locally advanced human bladder cancer
9. The retinoblastoma protein copurifies with E2F-1, an E1A-regulated inhibitor of the transcription factor E2F
10. The retinoblastoma tumor suppressor protein
11. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies
12. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas
13. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression
14. p53 mutations in human cancers
15. p53, the cellular gatekeeper for growth and division
16. Cancer. p53, guardian of the genome
17. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer
18. Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice
19. p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns
20. Accumulation of nuclear p53 and tumor progression in bladder cancer
21. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer
22. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value
23. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
24. Identification of p53 gene mutations in bladder cancers and urine samples
25. Expression of mutant p53, c-erbB- 2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder
26. Prognostic importance of p53 and Rb alterations in transitional cell carcinoma of the bladder
27. Correlation of p53 and retinoblastoma protein expression with established pathologic prognostic features in radical cystoprostatectomy specimens
28. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1
29. Induction of WAF1/CIP1 by a p53-independent pathway
30. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells
31. WAF1/CIP1 expression on tumor progression in bladder cancer
32. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder
33. Critical appraisal of tumor markers in bladder cancer
34. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: Its potential clinical importance
35. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67
36. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues
37. Monoclonal antibody Ki-67: Its use in histopathology
38. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma
39. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: Association with tumor progression
40. Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67)
41. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining